Abstract:Why antidepressants vary in terms of efficacy is currently unclear. Despite the leadership of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression, the precise neurobiological mechanisms involved in their therapeutic action are poorly understood. A better knowledge of molecular interactions between monoaminergic system, pre- and post-synaptic partners, brain neuronal circuits and regions involved may help to overcome limitations of current treatments and identify new therapeutic targets. Intracerebral in vivo microdialysis (ICM) already provided important information about the brain mechanism of action of antidepressants first in anesthetized rats in the early 1990s, and since then in conscious wild-type or knock-out mice. The principle of ICM is based on the balance between release of neurotransmitters (e.g., monoamines) and reuptake by selective transporters [e.g., serotonin transporter for serotonin 5-hydroxytryptamine (5-HT)]. Complementary to electrophysiology, this technique reflects pre-synaptic monoamines release and intrasynaptic events corresponding to ≈80% of whole brain tissue content. The inhibitory role of serotonergic autoreceptors infers that they limit somatodendritic and nerve terminal 5-HT release. It has been proposed that activation of 5-HT1A and 5-HT1B receptor sub-types limits the antidepressant-like activity of SSRIs. This hypothesis is based partially on results obtained in ICM experiments performed in naïve, non-stressed rodents. The present review will first remind the principle and methodology of ICM performed in mice. The crucial need of developing animal models that display anxiety and depression-like behaviors, neurochemical and brain morphological phenotypes reminiscent of these mood disorders in humans, will be underlined. Recently developed genetic mouse models have been generated to independently manipulate 5-HT1A auto and heteroreceptors and ICM helped to clarify the role of the pre-synaptic component, i.e., by measuring extracellular levels of neurotransmitters in serotonergic nerve terminal regions and raphe nuclei. Finally, we will summarize main advantages of using ICM in mice through recent examples obtained in knock-outs (drug infusion through the ICM probe allows the search of a correlation between changes in extracellular neurotransmitter levels and antidepressant-like activity) or alternatives (infusion of a small-interfering RNA suppressing receptor functions in the mouse brain). We will also focus this review on post-synaptic components such as brain-derived neurotrophic factor in adult hippocampus that plays a crucial role in the neurogenic and anxiolytic/antidepressant-like activity of chronic SSRI treatment. Limitations of ICM will also be considered.

Interest of using genetically manipulated mice as models of depression to evaluate antidepressant drugs activity: a review

Mutant mouse models and antidepressant drug research: focus on serotonin and brain-derived neurotrophic factor

Antidepressant activity: contribution of brain microdialysis in knock-out mice to the understanding of BDNF/5-HT transporter/5-HT autoreceptor interactions

Mouse Models for Studying Depression-Like States and Antidepressant Drugs

Gender differences in genetic mouse models evaluated for depressive-like and antidepressant behavior

The future of rodent models in depression research

Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters

Optogenetic and chemogenetic insights into the neurocircuitry of depression‐like behaviour: A systematic review

Animal Models of Depression: What Can They Teach Us about the Human Disease?

Treatment-resistant depression: are animal models of depression fit for purpose?

Mice genetically depleted of brain serotonin do not display a depression-like behavioral phenotype

Serotonin (5-HT) in the Regulation of Depression-Related Emotionality: Insight from 5-HT Transporter and Tryptophan Hydroxylase-2 Knockout Mouse Models

Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans

The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice

Animal models of major depressive disorder and the implications for drug discovery and development

Animal models of depression and anxiety: What do they tell us about human condition?

Animal models of major depression: drawbacks and challenges

The recent progress in animal models of depression

Rodent Models of Depression: Reexamining Validity Without Anthropomorphic Inference

Stress-based animal models of depression: Do we actually know what we are doing?